Olivia Yturralde

Biochemistry, Genetics and Molecular Biology · Life Sciences

4h-index304citations21works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PI3K/AKT/mTOR signaling in cancer(13), Lung Cancer Treatments and Mutations(9), Cancer Treatment and Pharmacology(4), Smoking Behavior and Cessation(2), Synthesis and biological activity(2)

Publications21 total

Supplementary Figure 5 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023Open Access
Supplementary Figure 6 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023Open Access
Supplementary Figure 1 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023Open Access
Supplementary Figure 2 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023Open Access
Supplementary Figure 4 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023Open Access
Data from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023Open Access
Data from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023Open Access
Supplementary Figure 4 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023Open Access
Supplementary Figure 3 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023Open Access
Supplementary Figure 6 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023Open Access
Supplementary Figure Legends, Tables 1 - 6 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023Open Access
Supplementary Figure 5 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023Open Access
Supplementary Figure Legends, Tables 1 - 6 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023Open Access
Supplementary Figure 2 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023Open Access
Supplementary Figure 3 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023Open Access
Supplementary Figure 1 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023Open Access
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
Molecular Cancer Therapeutics·2015· 54 citedOpen Access
Adherence to Varenicline Among African American Smokers: An Exploratory Analysis Comparing Plasma Concentration, Pill Count, and Self-report
Nicotine & Tobacco Research·2012· 25 citedOpen Access
Determination of the nicotine metabolites cotinine and trans-3′-hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography–tandem mass spectrometry: Biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity
Journal of Chromatography B·2010· 215 citedOpen Access
Biomarkers of Tobacco Exposure Are More Sensitive Than Smoking History in Critically Ill Adults.
2009
page 1 of 2Next →

Frequent Co-authors

Paul Foster(17), Toshihiro Yamaguchi(17), Pin P. Hsu(17), Fawn Qian(17), Xiangnan Du(17), Jianming Wu(17), Kwang‐Ai Won(17), Peiwen Yu(17), Christopher T. Jaeger(17), Charles K. Marlowe(17), Paul Keast(17), Wendy Abulafia(17), Jenny Young(17), Artur Płonowski(17), F. Michael Yakes(17), Felix Chu(17), Kelly Engell(17), Frauke Bentzien(17), Sanh T. Lam(17), Peter Lamb(17)